BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Voyer TL, Gitiaux C, Authier FJ, Bodemer C, Melki I, Quartier P, Aeschlimann F, Isapof A, Herbeuval JP, Bondet V, Charuel JL, Frémond ML, Duffy D, Rodero MP, Bader-Meunier B. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford) 2021:keab116. [PMID: 33576769 DOI: 10.1093/rheumatology/keab116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Olie C, Pinto-fernández A, Damianou A, Vendrell I, Mei H, Hamer BD, Wal EVD, de Greef J, raz V, Kessler B. USP18 is an essential regulator of muscle cell differentiation and maturation.. [DOI: 10.21203/rs.3.rs-2172567/v1] [Reference Citation Analysis]
2 Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J, Zou L, Xu Y, Xu X. Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr 2022;10:962585. [DOI: 10.3389/fped.2022.962585] [Reference Citation Analysis]
3 Elhage KG, Zhao R, Nakamura M. Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature. Clin Cosmet Investig Dermatol 2022;15:1815-31. [PMID: 36105749 DOI: 10.2147/CCID.S382628] [Reference Citation Analysis]
4 Tanboon J, Nishino I. Update on dermatomyositis. Curr Opin Neurol 2022. [PMID: 35942671 DOI: 10.1097/WCO.0000000000001091] [Reference Citation Analysis]
5 Shivpuri A, Turtsevich I, Solebo AL, Compeyrot-lacassagne S. Pediatric uveitis: Role of the pediatrician. Front Pediatr 2022;10:874711. [DOI: 10.3389/fped.2022.874711] [Reference Citation Analysis]
6 Ji-Xu A, Le ST, Maverakis E. Janus kinase inhibitors and risk of internal malignancy in dermatomyositis. J Dermatolog Treat 2022;:1-2. [PMID: 35694732 DOI: 10.1080/09546634.2022.2089323] [Reference Citation Analysis]
7 Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Naučno-praktičeskaâ revmatologiâ 2022;60:131-148. [DOI: 10.47360/1995-4484-2022-131-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hinze C, Dressler F, Schara-schmidt U, Haas J. Juvenile Dermatomyositis. Aktuelle Rheumatologie 2022;47:99-109. [DOI: 10.1055/a-1769-4299] [Reference Citation Analysis]
9 Olie CS, Pinto-fernández A, Damianou A, Abdellaoui SE, Vendrell I, Mei H, den Hamer B, van der Wal E, de Greef JC, van der Kooi AJ, Raaphorst J, Aronica E, Raz V, Kessler BM. USP18 is an essential regulator of muscle cell differentiation and maturation.. [DOI: 10.1101/2022.04.01.486741] [Reference Citation Analysis]
10 . Immune-globulin/immunosuppressants/Janus-kinase-inhibitors. Reactions Weekly 2022;1904:251-251. [DOI: 10.1007/s40278-022-14183-4] [Reference Citation Analysis]
11 Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol 2022. [PMID: 35209781 DOI: 10.1080/1744666X.2022.2047022] [Reference Citation Analysis]
12 Hou C, Periou B, Gervais M, Berthier J, Baba-amer Y, Souvannanorath S, Malfatti E, Relaix F, Bencze M, Authier FJ. Interferon-gamma mediates skeletal muscle lesions through JAK/STAT pathway activation in inclusion body myositis.. [DOI: 10.1101/2021.12.16.472927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang B, Chen S, Li Y, Xuan J, Liu Y, Shi G. Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now? BioDrugs 2021;35:593-610. [PMID: 34731460 DOI: 10.1007/s40259-021-00505-7] [Reference Citation Analysis]
14 Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J 2021;19:146. [PMID: 34563217 DOI: 10.1186/s12969-021-00637-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]